Revvity vs Sansure Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Revvity Inc. (RVTY)

Q3 202617 Jul – 9 Sep 2026

▲3

Revvity raises guidance, buys metabolic cell model maker

Revvity raises 2026 outlook after Q2 beat Revvity lifted full-year organic growth guidance to 4-5% and adjusted EPS to $5.30-$5.40, after Q2 adjusted EPS of $1.41 beat the high end. Diagnostics grew 11% organically, and management cited rising AI-related orders and a large instrument backlog. This directly improves the earnings outlook and supports a higher stock price.
The guidance raise is the single biggest new fundamental driver of RVTY's value this period.
Acquisition adds metabolic disease cell models Revvity agreed to buy France-based Human Cell Design, adding human pancreatic beta cell models for diabetes, obesity and GLP-1 research to its Life Sciences tools. The deal, expected to close in Q4 2026, expands its drug-discovery offerings and could lift future revenue, though terms were not disclosed.
A new acquisition expands RVTY's addressable market and product portfolio, a fresh positive catalyst.
New high-throughput TB testing platform Revvity developed the T-SPOT A201, an automated platform for latent tuberculosis testing that processes up to 384 samples per shift, targeted for launch in the second half of 2027. Shares rose 2.4% on the news. It strengthens Revvity's diagnostics franchise, though the launch is still over a year away.
A new product launch strengthens RVTY's diagnostics growth story and was a direct positive stock catalyst.
Q2 profit slips but revenue edges up Revvity's second-quarter profit fell to $51.8 million from $53.9 million a year earlier, while revenue rose 1.3% to $729.7 million. Adjusted EPS was $1.41. The profit decline is a mild negative, but the revenue growth and EPS beat the company's own guidance, so the overall signal is mixed.
The Q2 profit decline is a real counterweight to the positive guidance raise and acquisition news.

August 202617 Jul – 9 Sep 2026

▲3

Revvity raises guidance, buys metabolic cell model maker

Revvity raises 2026 outlook after Q2 beat Revvity lifted full-year organic growth guidance to 4-5% and adjusted EPS to $5.30-$5.40, after Q2 adjusted EPS of $1.41 beat the high end. Diagnostics grew 11% organically, and management cited rising AI-related orders and a large instrument backlog. This directly improves the earnings outlook and supports a higher stock price.
The guidance raise is the single biggest new fundamental driver of RVTY's value this period.
Acquisition adds metabolic disease cell models Revvity agreed to buy France-based Human Cell Design, adding human pancreatic beta cell models for diabetes, obesity and GLP-1 research to its Life Sciences tools. The deal, expected to close in Q4 2026, expands its drug-discovery offerings and could lift future revenue, though terms were not disclosed.
A new acquisition expands RVTY's addressable market and product portfolio, a fresh positive catalyst.
New high-throughput TB testing platform Revvity developed the T-SPOT A201, an automated platform for latent tuberculosis testing that processes up to 384 samples per shift, targeted for launch in the second half of 2027. Shares rose 2.4% on the news. It strengthens Revvity's diagnostics franchise, though the launch is still over a year away.
A new product launch strengthens RVTY's diagnostics growth story and was a direct positive stock catalyst.
Q2 profit slips but revenue edges up Revvity's second-quarter profit fell to $51.8 million from $53.9 million a year earlier, while revenue rose 1.3% to $729.7 million. Adjusted EPS was $1.41. The profit decline is a mild negative, but the revenue growth and EPS beat the company's own guidance, so the overall signal is mixed.
The Q2 profit decline is a real counterweight to the positive guidance raise and acquisition news.

Latest17 Jul – 9 Sep 2026

▲3

Revvity raises guidance, buys metabolic cell model maker

Revvity raises 2026 outlook after Q2 beat Revvity lifted full-year organic growth guidance to 4-5% and adjusted EPS to $5.30-$5.40, after Q2 adjusted EPS of $1.41 beat the high end. Diagnostics grew 11% organically, and management cited rising AI-related orders and a large instrument backlog. This directly improves the earnings outlook and supports a higher stock price.
The guidance raise is the single biggest new fundamental driver of RVTY's value this period.
Acquisition adds metabolic disease cell models Revvity agreed to buy France-based Human Cell Design, adding human pancreatic beta cell models for diabetes, obesity and GLP-1 research to its Life Sciences tools. The deal, expected to close in Q4 2026, expands its drug-discovery offerings and could lift future revenue, though terms were not disclosed.
A new acquisition expands RVTY's addressable market and product portfolio, a fresh positive catalyst.
New high-throughput TB testing platform Revvity developed the T-SPOT A201, an automated platform for latent tuberculosis testing that processes up to 384 samples per shift, targeted for launch in the second half of 2027. Shares rose 2.4% on the news. It strengthens Revvity's diagnostics franchise, though the launch is still over a year away.
A new product launch strengthens RVTY's diagnostics growth story and was a direct positive stock catalyst.
Q2 profit slips but revenue edges up Revvity's second-quarter profit fell to $51.8 million from $53.9 million a year earlier, while revenue rose 1.3% to $729.7 million. Adjusted EPS was $1.41. The profit decline is a mild negative, but the revenue growth and EPS beat the company's own guidance, so the overall signal is mixed.
The Q2 profit decline is a real counterweight to the positive guidance raise and acquisition news.

Sansure Biotech Inc (688289.CG)

Q3 202615 Jul – 27 Aug 2026

▼2▲1

Sansure's profit slumps on price cuts and tax hike despite new product approvals

First-half profit plunges 39.76% on price cuts and tax hike Sansure's first-half net profit fell 39.76% to 98 million yuan as reagent prices dropped from centralized procurement and medical insurance cost controls, and the VAT rate on test reagents jumped from 3% to 13%. This weak profit picture is the main force pushing the stock down.
This is the biggest new negative force on the stock and explains the core earnings deterioration.
Operating cash flow turns negative, adding financial strain The interim report showed operating cash flow was negative 15.66 million yuan, meaning the business burned cash in the first half. Combined with the profit drop, this raises concerns about near-term financial health and pressures the stock.
Negative cash flow is a new financial red flag that adds to the profit decline.
New product approvals expand testing menu and international reach Sansure won approvals for a Group A Streptococcus test, a freeze-dried four-in-one respiratory test, a dengue/chikungunya combo, and EU CE IVDR certification for five products including Class D HIV/HBV/HCV tests. These broaden future revenue sources and support long-term growth.
These approvals are the main positive pipeline news that could offset weak current earnings over time.
Dividend and shareholder enforcement send mixed signals Sansure plans a cash dividend of 2.65 yuan per 10 shares, returning about 151 million yuan to shareholders. But former shareholder Chen Wenyi faces judicial enforcement of 5.71 million shares (0.99% of capital), which could add selling pressure. The dividend supports the stock; the forced share sale weighs on it.
This captures both the positive capital return and the negative overhang from forced share sales.

August 202615 Jul – 27 Aug 2026

▼2▲1

Sansure's profit slumps on price cuts and tax hike despite new product approvals

First-half profit plunges 39.76% on price cuts and tax hike Sansure's first-half net profit fell 39.76% to 98 million yuan as reagent prices dropped from centralized procurement and medical insurance cost controls, and the VAT rate on test reagents jumped from 3% to 13%. This weak profit picture is the main force pushing the stock down.
This is the biggest new negative force on the stock and explains the core earnings deterioration.
Operating cash flow turns negative, adding financial strain The interim report showed operating cash flow was negative 15.66 million yuan, meaning the business burned cash in the first half. Combined with the profit drop, this raises concerns about near-term financial health and pressures the stock.
Negative cash flow is a new financial red flag that adds to the profit decline.
New product approvals expand testing menu and international reach Sansure won approvals for a Group A Streptococcus test, a freeze-dried four-in-one respiratory test, a dengue/chikungunya combo, and EU CE IVDR certification for five products including Class D HIV/HBV/HCV tests. These broaden future revenue sources and support long-term growth.
These approvals are the main positive pipeline news that could offset weak current earnings over time.
Dividend and shareholder enforcement send mixed signals Sansure plans a cash dividend of 2.65 yuan per 10 shares, returning about 151 million yuan to shareholders. But former shareholder Chen Wenyi faces judicial enforcement of 5.71 million shares (0.99% of capital), which could add selling pressure. The dividend supports the stock; the forced share sale weighs on it.
This captures both the positive capital return and the negative overhang from forced share sales.

Latest15 Jul – 27 Aug 2026

▼2▲1

Sansure's profit slumps on price cuts and tax hike despite new product approvals

First-half profit plunges 39.76% on price cuts and tax hike Sansure's first-half net profit fell 39.76% to 98 million yuan as reagent prices dropped from centralized procurement and medical insurance cost controls, and the VAT rate on test reagents jumped from 3% to 13%. This weak profit picture is the main force pushing the stock down.
This is the biggest new negative force on the stock and explains the core earnings deterioration.
Operating cash flow turns negative, adding financial strain The interim report showed operating cash flow was negative 15.66 million yuan, meaning the business burned cash in the first half. Combined with the profit drop, this raises concerns about near-term financial health and pressures the stock.
Negative cash flow is a new financial red flag that adds to the profit decline.
New product approvals expand testing menu and international reach Sansure won approvals for a Group A Streptococcus test, a freeze-dried four-in-one respiratory test, a dengue/chikungunya combo, and EU CE IVDR certification for five products including Class D HIV/HBV/HCV tests. These broaden future revenue sources and support long-term growth.
These approvals are the main positive pipeline news that could offset weak current earnings over time.
Dividend and shareholder enforcement send mixed signals Sansure plans a cash dividend of 2.65 yuan per 10 shares, returning about 151 million yuan to shareholders. But former shareholder Chen Wenyi faces judicial enforcement of 5.71 million shares (0.99% of capital), which could add selling pressure. The dividend supports the stock; the forced share sale weighs on it.
This captures both the positive capital return and the negative overhang from forced share sales.